Subsidiary company of Shenzhen Nanshan Power (000037.SZ) plans to invest in the construction of a 300MW/600MWh independent energy storage power station in the Cuiheng New Area of Zhongshan City (Phases Two and Three) project.

16:38 06/04/2026

Announcement of Shenzhen Energy Group Co., Ltd. (000037.SZ): In order to further utilize the site resources of the 300MW/600MWh independent energy storage power station project in Cuiheng New Area, Zhongshan City, the company plans to invest in the construction of the 300MW/600MWh independent energy storage power station project in Cuiheng New Area, Zhongshan City (Phase II, III) through its holding subsidiary, Shenzhen Energy Xiwang Energy (Zhongshan) Co., Ltd. (referred to as "Xiwang Company"). The project is planned to be built on the original site of Shenzhen Electric (Zhongshan) Power Co., Ltd. (referred to as "Zhongshan Company"), and the land leasing contract has not been signed yet. The total static investment of the project does not exceed 390 million yuan, with a unit cost not exceeding 0.973 yuan/Wh. Implementing this matter will help expand the company's energy storage business scale.

Shenzhen Nanshan Power (000037.SZ) announcement, the company plans to further leverage the site resources advantages of the Cuisheng New Area 300MW/600MWh independent energy storage power station (Phase I) project in Zhongshan City. It is planned to be invested and built by the holding subsidiary Shenzhen Nandian Xiwan Energy (Zhongshan) Co., Ltd. (referred to as "Xiwan Company") for the Cuisheng New Area 300MW/600MWh independent energy storage power station (Phase II, III) project. The project is planned to be built on the original site of Shenzhen Nandian (Zhongshan) Power Co., Ltd. (referred to as "Zhongshan Company"), and the land leasing contract has not been signed yet. The total static investment of the project does not exceed 390 million yuan, and the unit cost does not exceed 0.973 yuan/Wh. Implementing this project is beneficial for expanding the company's energy storage business scale.

China Securities Co., Ltd. reviews the A-share market in the first quarter of 2026: This bull market is more forward-looking in terms of regulation and will take timely measures to address overheated trading.

Jiangsu Aidea Pharmaceutical Group (688488.SH): A clinical trial for a new type 1 drug ACC085 injection in the field of HIV treatment will be conducted.

There is currently disagreement within OpenAI about when to IPO: Altman hopes for the fourth quarter, but the CFO believes they are not yet ready.

Jiangsu Aidea Pharmaceutical Group (688488.SH): A clinical trial for a new type 1 drug ACC085 injection in the field of HIV treatment will be conducted.

There is currently disagreement within OpenAI about when to IPO: Altman hopes for the fourth quarter, but the CFO believes they are not yet ready.